Recent stories
-
Two is Better Than One: Arming the T-Cells with Dual Cancer-Targeting Antibodies
One way to bring the powerful cellular immunity and antibody directed targeting together is to construct the chimeric antigen receptor (CAR) T-cells. In this strategy, the patient’s own T-cells are genetically engineered to produce a hybrid molecule (the CAR) on these killing cells.
-
Precision Medicine: New Technology That Changes the Clinical Practice
In order to monitor disease after a curative treatment such as allogeneic transplant, pioneer works from Drs. David Miklos and Wen-Kai Weng have established the utility of high-throughput sequencing (HTS) of either B-cell receptor (BCR) or T-cell receptor (TCR) in monitoring minimal residual disease (MRD).
-
Teaching a young dog new tricks: Story of a kinase and its inhibitor
The development of normal lymphocytes is a well-orchestrated process, that begins in the bone marrow. This process involves a functional antigen receptor (B-cell receptor or T-cell receptor) and a dozen of intermediators, including adaptor proteins and kinases that form a network of signaling pathways inside the cells.
-
The many challenges to success
Since the establishment of Stanford BMT program in 1987, many aspects of the clinical practice have changed.
-
Clinical Story: It Takes a World to Cure a Cancer
When Robin was first diagnosed with acute myeloid leukemia in December 2011, she knew that it would be a long journey for her fight against this cancer.
-
Translational Research: Cellular Therapeutics
While the graft-versus-tumor effect provided by the donor graft can be very powerful in controlling the disease, disease relapse is still the primary reason that patients do not do well after an allogeneic transplantation.
-
Bench to Bedside: Disruptive Innovation
While allogeneic transplantation can be life saving for patients with hematologic malignancies, or inherited disorders such as several forms of immuno-deficiency, the transplant-related side effects and complications remain the biggest hurdles.
-
The Modern-Day Magic Missile: Arming the T-Cells with Cancer-Targeting Antibody
When Kohler and Milstein developed hybridoma technology in 1975, a monoclonal antibody was thought to be the “Magic Bullet” to treat cancer since it can go directly to the targeted cancer cells.
-
Clinical Story: It Takes a Village to Cure a Cancer
When someone has mycosis fungoides, malignant cells in the blood travel to the skin, causing lesions that appear as an itchy rash.
-
Cellular Therapeutics: Release the Power of Individual Cellular Component
While the role for the individual cell population of the donor graft is not fully understood after allogeneic transplant, recent works in the field have yielded some interesting observations which may lead to advances in clinical care.